Business
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces
About this update from Biodesix, Inc.
[{"type":"text","content":" BOULDER, Colo.--(BUSINESS WIRE)--\nBiodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24, 2023, in Washington, DC.\n\n\nData from the abstract titled, Assessment of an Integrated Classifier’s Ability to Distinguish Benign from Malignant Nodules: Subgroup Analysis of the ORACLE Registry, presented by Dr. K. J. Long M.D. of the Medical University of South Carolina, SC, United States, will highlight data that show that the Negative Predictive Value for the Nodify XL2 test did not differ across multiple subgroups, including method of detection (incidental vs. screening), gender, smoking status or nodule size, suggesting that the test may be utilized effectively in a broad range of patient populations.\n\n\nAn additional presentation titled, Shifting the Intervention Probability Curve for Lung Cancer Diagnosis Following Biomarker Implementation: A Novel Clinical Endpoint for Biomarker Clinical Trials, presented by Dr. M. N. Kammer Ph.D. of Vanderbilt University Medical Center, TN, United States highlights that use of the Nodify XL2 test in the ORACLE registry study led to more appropriate usage of interventional procedures according to the patient’s probability of cancer, and suggests that an intervention probability analysis may prove useful for assessing clinical utility of biomarkers in future randomized trials.\n\n\nBoth poster presentations will occur during ATS discussion Session C99 – Advances in Biomarkers Across the Lung Cancer Continuum. The session, moderated by Dr. Anil Vachani M.D., MS from University of Pennsylvania Health System, Philadelphia, PA and Dr. Nichole Tanner, M.D., MSCR from Medical University of South Carolina, Charleston, SC, will occur at the ATS meeting on May 23rd, 2023, from 2:15-4:15PM, Room 202B (Level 2), Walter E. Washington Convention Center.\n\n\nAbout Biodesix\n\n\nBiodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omi...